Lung-RADS: Pushing the limits

Radiographics

Volumn 37, Issue 7, 2017, Pages 1975-1993

  Martin, Maria D ^a   Kanne, Jeffrey P ^a   Broderick, Lynn S ^a   Kazerooni, Ella A ^b   Meyer, Cristopher A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; HUMAN; LUNG TUMOR; METHODOLOGY; NORTH AMERICA; PRACTICE GUIDELINE; STANDARDS; UNITED STATES; X-RAY COMPUTED TOMOGRAPHY;

EARLY DETECTION OF CANCER; HUMANS; LUNG NEOPLASMS; NORTH AMERICA; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 85034612337     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.2017170051     Document Type: Article

References (55)

1. American College of Radiology. First edition of ACR Lung-RADS™ now available. American College of Radiology website. https://www.acr.org/About-Us/Media-Center/Press-Releases/2014-Press-Releases/First-Edition-of-ACR-LungRADS-Now-Available. Published May 1, 2014. Accessed March 9, 2017.
2. American College of Radiology. Lung-RADS™ version 1.0 assessment categories release date: April 28, 2014. American College of Radiology website. https://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/LungRADS/AssessmentCategories.pdf. Published April 28, 2014. Accessed March 9, 2017.
3. Centers for Medicare & Medicaid Services. Decision memo for screening for lung cancer with low dose computed tomography (LDCT) (CAG-00439N). Centers for Medicare & Medicaid Services website. https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274. Published February 5, 2015. Accessed March 9, 2017.
4. Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014; 160(5):330–338.
5. Fintelmann FJ, Bernheim A, Digumarthy SR, et al. The 10 pillars of lung cancer screening: rationale and logistics of a lung cancer screening program. RadioGraphics 2015;35(7):1893–1908.
6. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology 2017;284(1):228–243.
7. MacMahon H, Austin JH, Gamsu G, et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 2005;237(2):395–400.
8. Naidich DP, Bankier AA, MacMahon H, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology 2013;266(1):304–317.
9. Austin JH, Yip R, D’Souza BM, Yankelevitz DF, Henschke CI; International Early Lung Cancer Action Program Investigators. Small-cell carcinoma of the lung detected by CT screening: stage distribution and curability. Lung Cancer 2012;76(3):339–343.
10. Henschke CI, Yankelevitz DF, Yip R, et al. Lung cancers diagnosed at annual CT screening: volume doubling times. Radiology 2012;263(2):578–583.
11. Truong MT, Ko JP, Rossi SE, et al. Update in the evaluation of the solitary pulmonary nodule. RadioGraphics 2014;34(6):1658–1679.
12. Detterbeck FC, Gibson CJ. Turning gray: the natural history of lung cancer over time. J Thorac Oncol 2008;3(7):781–792.
13. Kauczor HU, Bonomo L, Gaga M, et al. ESR/ERS white paper on lung cancer screening. Eur Radiol 2015;25(9):2519–2531.
14. Brock University. Lung cancer risk calculators. Brock University website. https://brocku.ca/lung-cancer-risk-calculator. Published 2010. Accessed March 8, 2017.
15. Chestx-ray.com. Doubling time calculator. www.chestx-ray.com website. http://www.chestx-ray.com/index.php/calculators/doubling-time. Accessed March 8, 2017.
16. Huang Y, Xu Dm, Jirapatnakul A, et al. CT- and com-puter-based features of small hamartomas. Clin Imaging 2011;35(2):116–122.
17. Meisinger QC, Klein JS, Butnor KJ, Gentchos G, Leavitt BJ. CT features of peripheral pulmonary carcinoid tumors. AJR Am J Roentgenol 2011;197(5):1073–1080.
18. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008;246(3):697–722.
19. de Hoop B, Gietema H, van de Vorst S, Murphy K, van Klaveren RJ, Prokop M. Pulmonary ground-glass nodules: increase in mass as an early indicator of growth. Radiology 2010;255(1):199–206.
20. Kakinuma R, Muramatsu Y, Kusumoto M, et al. Solitary pure ground-glass nodules 5 mm or smaller: frequency of growth. Radiology 2015;276(3):873–882.
21. Sawada S, Komori E, Nogami N, Segawa Y, Shinkai T, Yamashita M. Evaluation of lesions corresponding to ground-glass opacities that were resected after computed tomography follow-up examination. Lung Cancer 2009;65(2):176–179.
22. Kakinuma R, Ashizawa K, Kuriyama K, et al. Measurement of focal ground-glass opacity diameters on CT images: interob-server agreement in regard to identifying increases in the size of ground-glass opacities. Acad Radiol 2012;19(4):389–394.
23. Heuvelmans MA, Oudkerk M. Management of subsolid pulmonary nodules in CT lung cancer screening. J Thorac Dis 2015;7(7):1103–1106.
24. Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev 2012;21(3):308–315.
25. Yousaf-Khan U, van der Aalst C, de Jong PA, et al. Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval. Thorax 2017;72(1):48–56.
26. van Riel SJ, Sánchez CI, Bankier AA, et al. Observer variability for classification of pulmonary nodules on low-dose CT images and its effect on nodule management. Radiology 2015;277(3):863–871.
27. Lindell RM, Hartman TE, Swensen SJ, Jett JR, Midthun DE, Mandrekar JN. 5-year lung cancer screening experience: growth curves of 18 lung cancers compared to histologic type, CT attenuation, stage, survival, and size. Chest 2009;136(6):1586–1595.
28. Ahn MI, Gleeson TG, Chan IH, et al. Perifissural nodules seen at CT screening for lung cancer. Radiology 2010;254(3):949–956.
29. Sykes AM, Swensen SJ, Tazelaar HD, Jung SH. Computed tomography of benign intrapulmonary lymph nodes: retrospective comparison with sarcoma metastases. Mayo Clin Proc 2002;77(4):329–333.
30. Shaham D, Vazquez M, Bogot NR, Henschke CI, Yankelevitz DF. CT features of intrapulmonary lymph nodes confirmed by cytology. Clin Imaging 2010;34(3):185–190.
31. Takenaka M, Uramoto H, Shimokawa H, et al. Discriminative features of thin-slice computed tomography for peripheral intrapulmonary lymph nodes. Asian J Surg 2013;36(2):69–73.
32. McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med 2013;369(10):910–919.
33. Williams OW, Sharafkhaneh A, Kim V, Dickey BF, Evans CM. Airway mucus: from production to secretion. Am J Respir Cell Mol Biol 2006;34(5):527–536.
34. Hong SR, Lee YJ, Hong YJ, et al. Differentiation between mucus secretion and endoluminal tumors in the airway: analysis and comparison of CT findings. AJR Am J Roentgenol 2014;202(5):982–988.
35. Bankier AA, O’Donnell CR, Boiselle PM. Quality initiatives: respiratory instructions for CT examinations of the lungs—a hands-on guide. RadioGraphics 2008;28(4):919–931.
36. Kim HJ, Kim DK, Kim YW, et al. Outcome of incidentally detected airway nodules. Eur Respir J 2016;47(5):1510–1517.
37. Brown SD. Professional norms regarding how radiologists handle incidental findings. J Am Coll Radiol 2013;10(4):253–257.
38. Nguyen XV, Davies L, Eastwood JD, Hoang JK. Extrapul-monary findings and malignancies in participants screened with chest CT in the National Lung Screening Trial. J Am Coll Radiol 2017;14(3):324–330.
39. Kazerooni EA, Austin JH, Black WC, et al. ACR-STR practice parameter for the performance and reporting of lung cancer screening thoracic computed tomography (CT): 2014 (resolution 4). J Thorac Imaging 2014;29(5):310–316.
40. Hoang JK, Langer JE, Middleton WD, et al. Managing incidental thyroid nodules detected on imaging: white paper of the ACR Incidental Thyroid Findings Committee. J Am Coll Radiol 2015;12(2):143–150.
41. Berland LL, Silverman SG, Gore RM, et al. Managing incidental findings on abdominal CT: white paper of the ACR Incidental Findings Committee. J Am Coll Radiol 2010;7(10):754–773.
42. Sebastian S, Araujo C, Neitlich JD, Berland LL. Managing incidental findings on abdominal and pelvic CT and MRI. IV. White paper of the ACR Incidental Findings Committee II on gallbladder and biliary findings. J Am Coll Radiol 2013;10(12):953–956.
43. Khosa F, Krinsky G, Macari M, Yucel EK, Berland LL. Managing incidental findings on abdominal and pelvic CT and MRI. II. White paper of the ACR Incidental Findings Committee II on vascular findings. J Am Coll Radiol 2013;10(10):789–794.
44. Heller MT, Harisinghani M, Neitlich JD, Yeghiayan P, Berland LL. Managing incidental findings on abdominal and pelvic CT and MRI. III. White paper of the ACR Incidental Findings Committee II on splenic and nodal findings. J Am Coll Radiol 2013;10(11):833–839.
45. Henschke CI, Lee IJ, Wu N, et al. CT screening for lung cancer: prevalence and incidence of mediastinal masses. Radiology 2006;239(2):586–590.
46. Mehta HJ, Mohammed TL, Jantz MA. The American College of Radiology Lung Imaging Reporting and Data System: potential drawbacks and need for revision. Chest 2017;151(3):539–543.
47. Ravenel JG, Tanner NT, Silvestri GA. Viewing all the trees in the forest: the importance of reporting abnormal findings on CT scan when screening for lung cancer. Chest 2017;151(3):525–526.
48. Jacobs PC, Gondrie MJ, van der Graaf Y, et al. Coronary artery calcium can predict all-cause mortality and cardiovascular events on low-dose CT screening for lung cancer. AJR Am J Roentgenol 2012;198(3):505–511.
49. Bernheim A, Auffermann WF, Stillman AE. The dubious value of coronary calcium scoring on lung cancer screening CT. J Am Coll Radiol 2017;14(3):343–344.
50. Hahm CR, Park HY, Jeon K, et al. Solitary pulmonary nodules caused by Mycobacterium tuberculosis and Mycobacterium avium complex. Lung 2010;188(1):25–31.
51. Onn A, Choe DH, Herbst RS, et al. Tumor cavitation in stage I non–small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. Radiology 2005;237(1):342–347.
52. Gill RR, Matsusoka S, Hatabu H. Cavities in the lung in oncology patients: imaging overview and differential diagnoses. Appl Radiol 2010. http://appliedradiology.com/articles/cavities-in-the-lung-in-oncology-patients-imaging-overview-and-differential-diagnoses. Published June 9, 2010. Accessed March 9, 2017.
53. Honda O, Tsubamoto M, Inoue A, et al. Pulmonary cavitary nodules on computed tomography: differentiation of malignancy and benignancy. J Comput Assist Tomogr 2007;31(6):943–949.
54. Woodring JH, Fried AM, Chuang VP. Solitary cavities of the lung: diagnostic implications of cavity wall thickness. AJR Am J Roentgenol 1980;135(6):1269–1271.
55. Jaklitsch MT, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg 2012;144(1):33–38.